US Patent 9657082 PD-L1 and PD-L2-based fusion proteins and uses thereof
Patent 9657082 was granted and assigned to Thomas Jefferson University on May, 2017 by the United States Patent and Trademark Office.
All edits
Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins.
US Patent 09657082 PD-L1 and PD-L2-based fusion proteins and uses thereof US Patent 9657082 PD-L1 and PD-L2-based fusion proteins and uses thereof
US Patent 09657082 PD-L1 and PD-L2-based fusion proteins and uses thereof
Find more entities like US Patent 9657082 PD-L1 and PD-L2-based fusion proteins and uses thereof
